Allstate
ALL
$232.60
+1.38%
The Allstate Corporation is one of the largest U.S. property-casualty insurers, underwriting personal auto, homeowners, and other insurance products sold primarily through roughly 6,000 exclusive agents across North America. It is a bellwether in the P&C sector, distinguished by its scale in personal auto, its multi-channel distribution model, and its expanding Protection Services platform, which bundles identity protection, device, and warranty products. The current investor narrative centers on a powerful earnings recovery driven by sharply lower catastrophe losses and disciplined auto rate increases, which have pushed quarterly net income to multi-billion-dollar levels and fueled aggressive share buybacks. At the same time, debate is building around whether this margin windfall is sustainable, with recent analyst downgrades (Citigroup to Sell, KBW to Underperform, Argus to Hold) and a softening stock price suggesting the market is questioning peak-cycle profitability.…
ALL
Allstate
$232.60
Related headlines
Investment Opinion: Should I buy ALL Today?
Based on the synthesis of data, the recommendation is Hold. The core thesis is that Allstate is a high-quality insurer trading at a deep discount on trailing earnings, but uncertainty about the sustainability of its recent profit surge and negative near-term momentum warrant a cautious stance. The analyst consensus rating of Hold (mean 2.52) and average target price of $270.55 (17.9% upside) support this view, suggesting the stock is fairly valued with limited near-term catalysts.
Supporting evidence includes the attractive valuation: trailing PE of 5.38x and forward PE of 8.20x, both well below the sector average of 12-18x. Revenue growth is solid at 12.39% YoY in Q2 2026, and profitability is strong with a 15.47% net margin and 33.59% ROE. Free cash flow of $12.25 billion TTM comfortably covers dividends and buybacks. However, the forward PE above trailing PE signals expected earnings decline, and the recent downgrades highlight concerns about peak-cycle profitability.
The biggest risks are a return to normal catastrophe losses, increased competition in auto insurance, and further multiple compression. The rating would upgrade to Buy if the stock stabilizes above $240 and earnings estimates for 2027 are revised upward, or downgrade to Sell if it breaks below $220 and analysts cut targets further. Relative to its history and peers, ALL appears undervalued on trailing metrics but fairly valued on forward estimates, reflecting the market's skepticism about earnings durability.
Sign up to view all
ALL 12-Month Price Forecast
Allstate presents a classic value trap dilemma: extremely cheap on trailing earnings but with clear signs of peak-cycle profitability. The 5.38x trailing PE and 33.59% ROE are impressive, but the higher forward PE and recent analyst downgrades suggest the market is correctly anticipating earnings normalization. The stock's low beta and 2.12% dividend yield make it a defensive holding, but near-term momentum is negative. I would upgrade to bullish if the company demonstrates sustainable underwriting margins above 20% for two consecutive quarters, and downgrade to bearish if catastrophe losses spike or auto competition intensifies. The risk/reward is balanced, favoring a Hold until clearer earnings visibility emerges.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Allstate's 12-month outlook, with a consensus price target around $270.55 and implied upside of +16.3% versus the current price.
Average Target
$270.55
0 analysts
Implied Upside
+16.3%
vs. current price
Analyst Count
—
covering this stock
Price Range
$191 - $336
Analyst target range
Allstate is covered by 22 analysts, with a consensus recommendation of Hold (recommendation mean of 2.52 on a scale where 1 is Strong Buy and 5 is Strong Sell), reflecting a distinctly neutral-to-cautious stance. The average target price of $270.55 implies approximately 17.9% upside from the current price of $229.43, which is a meaningful potential return but must be weighed against the Hold consensus and the recent wave of downgrades. The consensus leans neutral rather than bullish, with the Hold rating and the recent actions from Citigroup (downgrade to Sell), KBW (downgrade to Underperform), and Argus (downgrade to Hold) signaling that sell-side sentiment has deteriorated even as the average target remains above the current price. The target range is wide, from a low of $191.00 to a high of $336.00, a spread of $145 or roughly 63% of the current price, which signals high uncertainty about the company's earnings trajectory. The high target of $336 assumes that Allstate sustains its current underwriting profitability, benefits from continued favorable reserve development, and potentially expands its multiple as the market gains confidence in earnings durability; it may also reflect optimism about interest-rate-driven investment income. The low target of $191 prices in a normalization of catastrophe losses, competitive pressure in auto insurance, and potential margin compression as rate increases moderate, essentially a return to mid-cycle earnings. The institutional ratings pattern is notably negative, with three downgrades in August-September 2026 (Citigroup, KBW, Argus) against only reaffirmations from Mizuho, BMO, and JP Morgan, indicating that the balance of analyst opinion is shifting bearish. The estimated EPS average of $26.60 for the forward year, against the current trailing EPS of $12.66, implies analysts expect earnings to roughly double, which seems inconsistent with the forward PE being higher than the trailing PE and suggests either the trailing EPS figure is understated or the estimates are stale; this discrepancy warrants caution. Overall, the wide target spread, Hold consensus, and recent downgrade activity point to a stock in transition, where the market is debating whether the current earnings power is a new normal or a cyclical peak.
Bulls vs Bears: ALL Investment Factors
The bull case rests on deep value (5.38x trailing PE), robust cash flow ($12.25B TTM FCF), and a high ROE (33.59%), while the bear case emphasizes peak-cycle earnings, recent downgrades, and negative momentum. Currently, the bear evidence appears stronger: the forward PE above trailing PE, three analyst downgrades, and a 9.5% one-month decline suggest the market is pricing in normalization. The most critical tension is whether the current earnings power is sustainable or a cyclical peak—if Allstate can maintain even a portion of its recent profitability, the stock is undervalued; if not, further downside is likely.
Bullish
- Deep Value on Trailing Earnings: ALL trades at a trailing PE of just 5.38x, far below the 12-18x typical for large-cap P&C insurers. With Q2 2026 net income of $3.273 billion and EPS of $12.66, the market is pricing in a severe earnings collapse that may not materialize.
- Robust Free Cash Flow Generation: TTM free cash flow stands at $12.249 billion, easily covering the $310 million quarterly dividend and $1.051 billion in buybacks. This self-funding capacity supports continued capital returns and provides a margin of safety.
- Exceptional Profitability Metrics: ROE of 33.59% and net margin of 15.47% are outstanding for the insurance sector. Q2 2026 net income surged 55% YoY to $3.273 billion, driven by lower catastrophe losses and disciplined underwriting.
- Analyst Target Implies Significant Upside: The average analyst target price of $270.55 represents 17.9% upside from the current $229.43. Even the low target of $191 is only 16.7% below current levels, suggesting limited downside according to sell-side models.
Bearish
- Earnings Sustainability Questioned: The forward PE of 8.20x is higher than the trailing PE of 5.38x, implying analysts expect earnings to decline from current elevated levels. This peak-cycle signal suggests the market doubts the durability of recent profits.
- Recent Analyst Downgrades: Citigroup downgraded to Sell, KBW to Underperform, and Argus to Hold in August-September 2026. The consensus recommendation is Hold with a mean of 2.52, reflecting a cautious stance despite the high average target.
- Negative Price Momentum: The stock is down 9.52% over the past month and 8.82% over three months, significantly underperforming the S&P 500. Relative strength versus SPY is -11.64% over one month, indicating capital rotation away from the name.
- Catastrophe Loss Exposure: As a P&C insurer, Allstate's earnings are highly sensitive to catastrophe losses. The current windfall is partly due to a quiet catastrophe year, which is unlikely to persist indefinitely, posing a risk to future profitability.
ALL Technical Analysis
Allstate is in a broad recovery uptrend that has stalled in recent months, with the stock up 9.78% over the past year but trading at 229.43, which is only about 47.5% of its 52-week range (52-week low of 188.08, high of 277.22). That mid-range positioning signals neither momentum leadership nor deep-value territory, but rather a market that has taken profits after a strong run and is now reassessing the earnings trajectory. The 52-week high of 277.22 was set in early August, and the failure to reclaim it despite a 12.57% YTD gain suggests waning upside conviction. Recent momentum has deteriorated sharply, with the stock down 9.52% over the past month and 8.82% over three months, a stark deceleration from the 8.74% gain over six months. This divergence between a positive 1-year trend and negative 1-month and 3-month performance is a classic late-cycle warning: the stock has lost relative strength versus the S&P 500 by 11.64% over one month and 11.95% over three months, meaning capital is rotating away from Allstate even as the broader market (SPY +2.12% 1-month, +16.0% 1-year) advances. The September selloff from 258.48 on September 14 to 221.86 on September 30, a roughly 14% drop in two weeks, confirms that sellers are in control of the near-term tape. Key technical support sits at the 52-week low of 188.08, with intermediate support around the 220-225 area where the stock has recently stabilized; resistance is defined by the 52-week high of 277.22 and the 260-265 zone that capped multiple rallies in August and September. A breakout above 265 would signal renewed institutional accumulation and a likely retest of the highs, while a breakdown below 220 would open the door toward the 188 low and validate the bearish downgrade thesis. Notably, the beta of 0.138 indicates Allstate is far less volatile than the broader market, which is typical for a large-cap insurer but also means the stock lacks the high-beta torque that drives sharp rallies; position sizing should reflect this low-volatility, income-oriented profile.
Beta
0.14
0.14x market volatility
Max Drawdown
-19.4%
Largest decline past year
52-Week Range
$188-$277
Price range past year
Annual Return
+13.1%
Cumulative gain past year
| Period | ALL Return | S&P 500 |
|---|---|---|
| 1m | -8.3% | +1.8% |
| 3m | -7.1% | +3.5% |
| 6m | +6.6% | +11.2% |
| 1y | +13.1% | +19.1% |
| ytd | +14.1% | +14.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ALL Fundamental Analysis
Allstate's revenue trajectory is solidly growing, with Q2 2026 revenue of $18.596 billion representing 12.39% year-over-year growth versus Q2 2025's $16.546 billion. The multi-quarter trend shows consistent expansion: Q1 2026 revenue was $16.941 billion, Q4 2025 was $16.59 billion, and Q3 2025 was $17.061 billion, indicating that the top line has stabilized in the $16.5-18.6 billion quarterly range with a clear upward bias. The Protection Services segment contributed $915 million, a small but strategically important piece of the portfolio that diversifies away from pure auto and home risk. The acceleration in Q2 2026 revenue growth to 12.39% YoY, combined with the company's estimated full-year revenue of approximately $64.06 billion, implies the growth story remains intact even as the stock price has pulled back, creating a potential disconnect between fundamentals and sentiment. Profitability has inflected dramatically: Q2 2026 net income was $3.273 billion with a net margin of 17.6%, up from $2.109 billion and a 12.75% net margin in Q2 2025, a 55% increase in absolute profit. Gross margin in Q2 2026 was 34.75%, while operating margin was 22.8% and EBITDA margin was 23.0%, reflecting the powerful combination of lower catastrophe losses and improved underwriting discipline. The quarterly progression is equally impressive: Q1 2026 net income of $2.458 billion (14.5% net margin) and Q4 2025 net income of $3.832 billion (23.1% net margin) show that the company has moved well past the loss-making quarters of 2023, when Q2 2023 posted a negative 9.75% net margin. The balance sheet is conservatively managed, with a debt-to-equity ratio of just 0.2447 and a debt ratio of 0.060, well below the leverage levels seen in 2022-2023 when D/E exceeded 0.40. Free cash flow is robust at $12.249 billion TTM, with Q2 2026 free cash flow of $2.591 billion and Q1 2026 of $3.522 billion, easily covering the $310 million in quarterly dividends and $1.051 billion in buybacks. The ROE of 33.59% is exceptional for the insurance sector and reflects both strong earnings and an efficient capital structure, while the current ratio of 0.37 is low but typical for insurers whose business model relies on float rather than working capital. The company's ability to generate over $12 billion in annual free cash flow while returning capital through dividends (2.12% yield) and buybacks demonstrates self-funding capacity with minimal reliance on external financing.
Quarterly Revenue
$18.6B
2026-06
Revenue YoY Growth
+12.4%
YoY Comparison
Gross Margin
34.8%
Latest Quarter
Free Cash Flow
$12.2B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ALL Overvalued?
Because Allstate is solidly profitable with trailing net income of $3.273 billion in the most recent quarter and positive EPS of $12.66, the PE ratio is the appropriate primary valuation metric. The trailing PE of 5.38x is extraordinarily low in absolute terms, while the forward PE of 8.20x is higher, implying the market expects earnings to decline from the current elevated level, a classic peak-cycle signal. The gap between trailing and forward PE (5.38x vs. 8.20x) suggests analysts are modeling normalized earnings well below the current catastrophe-light windfall, which is a critical consideration for valuation. Relative to the broader Financial Services and P&C insurance sector, where large-cap insurers typically trade at 12-18x earnings, Allstate's trailing PE of 5.38x represents a discount of roughly 55-70%, while its forward PE of 8.20x still implies a 30-50% discount. This deep discount is partially justified by the cyclicality of catastrophe losses and the market's skepticism about earnings sustainability, but it also reflects genuine value if the company can maintain even a portion of its current profitability. The PS ratio of 0.82x and EV/Sales of 0.885x are also low for a company with a 15.5% net margin, while the PB ratio of 1.78x is reasonable given the 33.59% ROE. Historically, Allstate's PE ratio has ranged from negative territory during loss years (2022-2023) to a high of 35.2x in Q2 2024, with more normal periods trading between 6x and 10x. The current trailing PE of 5.38x is near the low end of its historical profitable range, while the forward PE of 8.20x is mid-range, suggesting the market is pricing in a normalization of earnings rather than a collapse. The dividend yield of 2.12% and payout ratio of just 11.2% provide a margin of safety and room for continued capital returns, supporting the view that the stock is not expensive on a cash-flow basis despite the recent price weakness.
PE
5.4x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 4x~24x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
4.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on the sustainability of Allstate's recent earnings surge. The company's Q2 2026 net income of $3.273 billion benefited from a quiet catastrophe year, and any return to normal catastrophe activity could significantly reduce profitability. Additionally, the debt-to-equity ratio of 0.2447, while conservative, still exposes the company to interest rate risk, and the low current ratio of 0.37 reflects the insurer's reliance on float, which could strain liquidity if claims surge. Furthermore, the forward PE of 8.20x versus trailing 5.38x indicates analysts expect earnings to decline, highlighting the risk of margin compression as auto rate increases moderate and competitive pressures intensify.
Market and competitive risks include valuation compression if the stock's premium multiple erodes further. Although ALL trades at a discount to peers, the recent downgrades by Citigroup, KBW, and Argus reflect growing skepticism about the earnings trajectory. The stock's low beta of 0.138 means it lacks high-beta torque but also makes it sensitive to sector rotation, as evidenced by its 11.64% underperformance versus the S&P 500 over the past month. Regulatory headwinds, such as potential rate rollbacks in key states, could further pressure margins, while intense competition in personal auto insurance may limit pricing power.
The worst-case scenario involves a combination of a return to normal catastrophe losses, heightened auto insurance competition, and a broader market downturn. In this scenario, Allstate's earnings could revert to mid-cycle levels, pushing the stock toward its 52-week low of $188.08, representing a 18.0% decline from the current price of $229.43. The analyst low target of $191 implies a similar downside of 16.7%. If the company fails to sustain its underwriting profitability, the stock could test these levels, especially if the market begins to price in a recession or a prolonged period of elevated catastrophe claims.
FAQ
The most severe risk is earnings sustainability: the forward PE above trailing PE indicates analysts expect a decline, and a return to normal catastrophe losses could slash profits. Competitive risk is also high, with intense auto insurance competition potentially eroding margins. Macro risk includes sensitivity to interest rates and sector rotation, as shown by the 11.64% underperformance versus the S&P 500 over the past month. Company-specific risks include regulatory rate rollbacks and reserve deficiencies. Ranked by severity: 1) catastrophe loss normalization, 2) competitive margin pressure, 3) multiple compression, and 4) regulatory headwinds.
The 12-month forecast is base case (55% probability) targeting $240-280, assuming earnings normalize to sustainable levels and the stock achieves the average analyst target of $270.55. The bull case (25%) targets $280-336 if underwriting profitability persists and multiple expands. The bear case (20%) targets $188-220 if catastrophe losses spike and competition intensifies. The most likely scenario is the base case, hinging on Allstate maintaining a combined ratio below 95% and continued capital returns. Key catalysts include Q3 earnings and reserve development.
ALL appears undervalued on trailing metrics but fairly valued on forward estimates. The trailing PE of 5.38x is significantly below the 12-18x typical for large-cap P&C insurers, suggesting a deep discount. However, the forward PE of 8.20x is higher, implying the market expects earnings to decline from current levels. The PS ratio of 0.82x and EV/EBITDA of 4.36x are also low, reflecting skepticism about earnings durability. Relative to its own history, the trailing PE is near the low end of its profitable range, while the forward PE is mid-range. The market is pricing in a normalization of earnings, not a collapse, so the stock is not overvalued but lacks a clear catalyst for multiple expansion.
ALL is a good buy for value-oriented investors with a long-term horizon, given its trailing PE of 5.38x and 17.9% upside to the average analyst target of $270.55. However, the Hold consensus and recent downgrades suggest near-term caution. The biggest downside risk is a return to normal catastrophe losses, which could push the stock toward its 52-week low of $188.08, an 18% decline. For income investors, the 2.12% dividend yield and low beta of 0.138 add appeal. Overall, it is a nuanced buy: attractive for those who believe earnings are sustainable, but risky for momentum traders.
ALL is better suited for long-term investment, given its low beta of 0.138, stable dividend yield of 2.12%, and cyclical earnings that require time to normalize. Short-term trading is risky due to negative momentum (-9.52% over one month) and high uncertainty around catastrophe losses. The stock's earnings visibility is moderate, with quarterly volatility from weather events. A minimum holding period of 2-3 years is recommended to ride out the insurance cycle and benefit from potential multiple expansion. Income investors may appreciate the consistent dividends, while value investors should wait for clearer signs of sustainable profitability.